Question 1

Which of the following best describes the main finding regarding the effectiveness of population genetic screening for CDC Tier 1 (CDCT1) conditions in the Healthy Nevada Project (HNP)?

Accepted Answer

Population genetic screening identified over 90% of at-risk carriers who would not have been detected by current medical practice.

Question 2

Which genes are associated with Lynch syndrome (LS) as studied in the HNP cohort?

Accepted Answer

MLH1, MSH2, MSH6, PMS2

Question 3

A 45-year-old male is found to carry a pathogenic variant in LDLR. Based on the study findings, what is the most likely clinical implication for this individual compared to non-carriers?

Accepted Answer

He is more likely to develop hyperlipidemia at an earlier age.

Question 4

Which statistical test was primarily used to compare disease-free survival (DFS) between carriers and non-carriers in the study?

Accepted Answer

Two-sided log-rank test

Question 5

What was the combined carrier rate for pathogenic and likely pathogenic variants in HBOC, LS, and FH in the HNP cohort?

Accepted Answer

$$1.33\%$$

Question 6

Which of the following statements about the age of disease onset in CDCT1 carriers is supported by the study?

Accepted Answer

Most clinically relevant disease in carriers presents after age 40, with 70% presenting before age 65.

Question 7

Which of the following best explains why average-risk screening protocols may not be sufficient for CDCT1 carriers?

Accepted Answer

CDCT1 carriers have an accelerated risk of disease that often manifests before the age at which average-risk screening begins.

Question 8

In the context of the study, what does an odds ratio (OR) of 9.9 for breast or ovarian cancer in HBOC carriers compared to non-carriers indicate?

Accepted Answer

HBOC carriers are nearly 10 times more likely to develop breast or ovarian cancer than non-carriers.

Question 9

Which of the following is a limitation of the HNP study as described in the methods?

Accepted Answer

The analysis was limited to small variants and did not include copy number variants.

Question 10

A patient with a pathogenic variant in MSH6 is compared to a patient with a PMS2 variant. According to the study, which is more likely?

Accepted Answer

The MSH6 variant carrier has a higher penetrance for LS-associated cancers.

Question 11

Which of the following best describes the impact of family history on disease risk among carriers, as found in the study?

Accepted Answer

Carriers who also have a family history of disease are at even higher risk than carriers without family history.

Question 12

Which of the following is NOT a gene associated with familial hypercholesterolemia (FH) in the HNP study?

Accepted Answer

BRCA2

Question 13

What is the main public health implication of the HNP study findings?

Accepted Answer

Population genetic screening can identify at-risk individuals who would otherwise be missed by current guidelines, enabling earlier intervention.

Question 14

Which of the following best describes the consent process for HNP participants?

Accepted Answer

Participants provided written informed consent for sequencing, linking data with health records, and optional return of secondary findings.

Question 15

Which formula would you use to calculate the odds ratio (OR) for disease in carriers versus non-carriers?

Accepted Answer

$$OR = \frac{(a/c)}{(b/d)}$$, where $$a = $$carriers with disease, $$b = $$carriers without disease, $$c = $$non-carriers with disease, $$d = $$non-carriers without disease.

Question 16

A 35-year-old woman with no family history of breast or ovarian cancer is found to carry a BRCA1 pathogenic variant. According to the study, what is the most appropriate clinical recommendation?

Accepted Answer

She should be considered at increased risk and may benefit from earlier and more frequent cancer screening.

Question 17

Which of the following best describes the difference in disease-free survival (DFS) between BRCA1 and BRCA2 carriers for HBOC in the HNP cohort?

Accepted Answer

There was no significant difference in DFS between BRCA1 and BRCA2 carriers.

Question 18

Which of the following is a potential ethical concern with population genetic screening as discussed in the study?

Accepted Answer

Overinterpretation of disease risk and added costs to the healthcare system.

Population Genetic Screening for Autosomal Dominant Diseases: Insights from the Healthy Nevada Project

Guida di studio - Domande di pratica

Study guide - Flashcard